Background. Lung transplantation is the treatment of choice for patients with end-stage lung failure. Limitations are presented by the shortage of donors and the long waiting list periods. New techniques, such as extracorporeal membrane ventilator devices with or without pump support, have been developed as bridges to transplantation for patients with severe, unresponsive respiratory insufficiency. Methods. Between
T HE NUMBER OF patients listed for lung transplantation (LT) is continuously rising. Even if LT procedures are annually increasing, the number of patients awaiting LT still overwhelms the number of available grafts. 1 Alternative solutions as bridges to transplantation or to recovery, especially for acute pulmonary failure, are becoming more important. Critically ill patients with severe pulmonary distress, characterized by respiratory insufficiency with severe hypoxemia and hypercapnia, often require invasive ventilatory support. Mechanical ventilation forces the lungs to work under nonphysiologic positive pressure. This condition, even with protective respiratory settings (low tidal volumes), cause barotrauma, volutrauma, and biotrauma. 2 In addition, it increases the risk of lung injury, infection, atelectasis, muscle fatigue, and remote organ failure. 3, 4 It is recognized to be a significant risk factor for mortality after LT. 5 Despite maximal mechanical ventilatory support, most patients develop refractory hypercapnia and acidosis that require additional extracorporeal gas exchange.
Alternatives to extracorporeal membrane oxygenation (ECMO), which has been widely used until now, are new devices such as the interventional lung assist NovaLung (ILA; NovaLung GmbH, Hecnigen, Germany) and the decapneization system Decap. [6] [7] [8] The ILA is a low-resistance lung assist device driven by the cardiac output that does not require extracorporeal pump assistance; it provides venoarterious passive carbon dioxide removal via a diffusion membrane. In contrast, the Decap system allows venovenous extracorporeal CO 2 removal using a mini-invasive pump. Herein we have reported our experience with both devices as bridges to transplantation among patients with severe and unresponsive pulmonary failure on the waiting list for LT.
MATERIALS AND METHODS
From November 2005 to September 2009, 12 LT waiting list patients (7 males, 5 females) of overall mean age of 43.3 Ϯ 15.5 years were treated with extracorporeal devices for CO 2 removal because of severe ventilation-refractory hypercapnia with respiratory acidosis. In 6 patients, the Decap system was used; the other 6 underwent ILA implantation. The decision on which device was made on the basis of the hemodynamic capability of the patient to sustain extracorporeal gas exchange with or without the interposition of a centrifugal pump. Patients with an adequate mean arterial pressure (MAP) to drive blood through the system were treated with the pumpless apparatus (ILA). Those subjects who were not able to sustain an extracorporeal gas exchange were supported with a Decap device. No difference was noted in terms of patient characteristics between the 2 groups (data not shown).
The Novalung was implanted using the standard technique. 9 For the Decap system, cannulation consisted of insertion of a percutaneous single access with a double lumen catheter connected to a venovenous circuit driven by a low-flow pump (Ͻ40 mL/min). A heparin bolus (5000 IU) was administered intravenously followed by titrated administration to maintain the activated clotting time between 150 and 200 sec. Administration of fluids as well as vasopression or inotropic agents was targeted to maintain a MAP of 65 mm Hg. 7, 8 Perfusion of the lower extremities was examined daily with a Doppler examination.
In all patients, arterial blood gas samples were obtained at the time of the implantation as well as at 1, 2, 3, and 7 days after implantation.
Statistical Analysis
Data are presented as mean values Ϯ SD, medians (ranges), or frequencies (percents). Patients characteristics among the femoral and direct aortic cannulation groups were compared using Student's t-test. Statistical significance was accepted for P Ͻ .05.
RESULTS
All patients except 1 were on mechanical ventilatory support before device implantation. The indication for decapneization device implantation was severe hypercapnia and acidosis refractory to positive high pressure mechanical ventilation. The only subject not on a ventilator was a lung transplant patient treated with ILA because of respiratory failure owing to worsening chronic rejection. This not intubated patient has been on ILA assistance awaiting lung retransplantation. The original lung diseases were cystic fibrosis (n ϭ 6), pulmonary emphysema (n ϭ 5), and chronic rejection in a previous double lung transplantation (n ϭ 1, Table 1 ). The global mean duration of decapneization support was similar between ILA and Decap, namely, 13.5 Ϯ 14.2 days (median, 7.5; range, 4 -48). Pre-and postimplant changes in blood gases are shown in Figure 1 . There was a significant reduction in PaCO 2 levels at 24, 48, and 72 hours postimplantation for both extracorporeal systems. No significant difference was noted at any time in terms of PaO 2 levels either before or after device implantation or either with the ILA or Decap system. Because of thrombosis of the ILA, a membrane replacement was required while cannulas were left in place in 1 case. One patient was first weaned from the ventilator and later from the Decap for a total device period of 11 days. This patient is still awaiting double lung transplantation. Three patients (25%) were successfully transplanted; the remaining 8 succumbed under decapneization treatment. The causes of death are summarized in Table 2 .
DISCUSSION
The aim of insertion of percutaneous extracorporeal lung assistance devices is to allow lung protective ventilation, to improve gas exchange, and at the same time, to reduce the lung damage due to high-pressure-high-volume mechanical ventilation. In this way, native lung function is supported, the diseased lung may better and more quickly recover from acute respiratory failure as artificial ventilation can be downgraded. Our results confirmed the decapneization efficacy of ILA and Decap at 24, 48, and 72 hours postimplantation among waiting list patients for LT with acute respiratory failure refractory to mechanical high-pressure ventilator support. No difference in PaCO 2 before versus after implantation has been observed, for either device, after 7 days of extracorporeal CO 2 removal. These data must be critically analyzed, taking into account that 50% of patients were affected by cystic fibrosis and 6/12 had a duration of extracorporeal support Ͻ7 days: 3 underwent lung transplantation and 3 died on the device because of severe pseudomonas pneumonia. No improvements in blood oxygenation were observed with device implantation, which correlates with the purpose and design of both systems. In our experience, the decision as to the device was made on the basis of the hemodynamic conditions. For patients with an adequate MAP, we used a pumpless apparatus (ILA); in others, we preferred a Decap device. Thus, hemodynamic judgment before insertion of such devices is mandatory. For that purpose echocardiography must be performed to assess myocardial function and estimate cardiac index. An alternative, when possible, is Swan-Ganz catheterization, which may be beneficial to define the assistance device.
We found no difference between the 2 extracorporeal assistance techniques, a finding that permitted us to extend the indication for extracorporeal decapneization to patients who previously would have been treated with ECMO and/or high-pressure mechanical ventilation, 2 conditions that are widely recognized to negatively affect LT outcomes. Moreover, ECMO is associated with various side effects, such as infections, renal insufficiency, hemolysis, and bleeding complications. 10 In contrast, invasive, high-pressure mechanical ventilation is responsible for various forms of lung damage: barotaruma, volutrauma, biochemical trauma, and atelectrauma, ventilator-associated lung injuries. 2, 9, 10 In severe cases, mechanical ventilation under high volume and positive pressure is an additional option, although it is well known to be a risk factor for post-LT mortality 5, 11, 12 and should be avoided under such circumstances if possible.
The decapneization systems were clearly efficient in cases of severe hypercapnia but with mild to moderate hypoxia. Venoarterious ECMO remains the only solution for severely hypoxic patients.
In conclusion, the extracorporeal assistance devices used in our center were clearly efficient, safe methods to support patients with deteriorating gas exchange thereby avoiding any further ventilation-induced lung injury. Elimination of carbon dioxide is more effective than oxygenation. Thus, indications for these systems remain severe hypercapnia and respiratory acidosis with moderate hypoxia, especially as a bridge to transplantation or recovery among patients either on the waiting list or experiencing primary graft dysfunction. Pumpless assistance and low-flow, pumpdriven devices showed similar results, permitting us to extend the indications also to patients previously eligible only for ECMO. The limited number of LT performed due to the limited availability of lung donors remains the major problem for patients assisted with these devices. Figure 2 . 
